In preclinical models, ATM and ATR inhibitors together with IR created a more favorable anti-tumor immune microenvironment (e.g. increased cytotoxic T-cells, decreased Tregs), increased T-cell receptor diversity, generated immunologic memory and combined with immunotherapies improved tumor control83–86. This evidence concerns the gene ATM and neoplasm.